

1 **Microbial biofilms: biosurfactants as antibiofilm**
2
3
4 **agents**
5
6
7
8
9

10
11 Ibrahim M Banat^{1*}, Mayri A. Díaz De Rienzo and Gerry A. Quinn³
12
13
14
15

16 ¹ School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern
17
18 Ireland, UK.
19
20

21 ² School of Chemical Engineering and Analytical Science, University of Manchester,
22
23 Manchester, UK.
24
25

26 ³ College of Medicine, Swansea University, Swansea, SA2 8PP, Wales, UK.
27
28
29
30
31
32

33 **Key words:** Biosurfactants, biofilm, disruption, antimicrobial, antibiofilm, dispersal
34
35 agents, adjuvants.
36
37
38
39

40 * Corresponding author email: im.banat@ulster.ac.uk
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Current microbial inhibition strategies based on planktonic bacterial physiology have been known to have limited efficacy on the growth of biofilms communities. This problem can be exacerbated by the emergence of increasingly resistant clinical strains. All aspects of biofilm measurement, monitoring, dispersal, control and inhibition are becoming issues of increasing importance. Biosurfactants have merited renewed interest in both clinical and hygienic sectors due to their potential to disperse microbial biofilms in addition to many other advantages. The dispersal properties of biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial and yeasts biofilms. This makes them suitable candidates for use in new generations of microbial dispersal agents and for use as adjuvants for existing microbial suppression or eradication strategies. In this review we explore aspects of biofilms characteristics and examine the contribution of biologically derived surface-active agents (biosurfactants) to the disruption or inhibition of microbial biofilms.

Introduction

Microorganisms in general gravitate towards solid surfaces forming biofilms as a strategy to protect themselves from environmental challenges. Such deposition and subsequent biofilm formation is a phenomenon that happens naturally and is usually part of the microorganisms' strategy to protect themselves from external toxic factors (Pereira et al. 2007). They have the ability to sense their own cell density, communicate and behave as a population through cell to cell signalling, a phenomenon known as quorum-sensing (Liu et al. 2012). This behaviour has been documented for some time in microbial biofilm formations (Davies 2003) and is dependent on the nutritional/environment and the maturation stage of development of the microorganisms. Microbial biofilms represent a distinct bacterial physiology characterised by a multicellular phenotype that is fundamentally different from planktonic bacteria. They have been implicated in chronic and recalcitrant healthcare associated infections (Dowd et al. 2008), the dissemination of community acquired diseases (Stewart et al. 2012), effective hygienic processing, increased failure rate of anti-infective therapy (Bueno, 2014) and marine water and electronics environments (Lourenco et al. 2011). Biofilms that are composed of one species are relatively rare in the majority of the natural environment; rather microorganisms tend to be found in complex multispecies communities associated with surfaces (Stoodley et al. 2002).

Until recently the differences between planktonic and biofilm physiologies seemed inconsequential. Standard bacterial inhibition tests were almost exclusively based on planktonic bacterial physiology and not the biofilm physiology even though these conditions were not readily observed in the natural environment. The standard planktonic bacterial physiology is typically exemplified by free-living single bacteria with optimal nutrition, gas exchange and agitation (typically 250rpm) (Bueno 2014; Kotulova and Slobodnikova, 2010).

In contrast, the biofilm physiology has multicellular differentiation, multicellular communication, internal architecture and rudimentary fluid transport systems (Girard et al. 2010; Leis et al. 2005). More importantly for in-vitro testing procedures, biofilms have variable levels of nutrients, gas exchange, little or no agitation and therefore slower growth.

1 This difference in bacterial physiology can be critical especially in clinical situations where
2 there is a higher production of virulence factors in pathogens such as *Pseudomonas*
3 *aeruginosa* (Croda-García et al. 2011). In the biofilm physiology these pathogens can be one
4 to three orders of magnitude more resistant to dispersal/inhibition by conventional
5 chemotherapy than their planktonic counterparts of the same species (Girard et al. 2010;
6 Olson et al. 2002; Sepandj et al. 2004). This has been demonstrated in recent experiments
7 on biofilm formation during peritoneal dialysis, where all the antibiotics tested were effective
8 in laboratory MIC tests but (with the exception of gentamicin) lost their efficacy against
9 *Staphylococcus aureus* biofilms (Girard et al. 2010). Globally, methicillin resistant
10 *Staphylococcus aureus* (MRSA) is a serious problem due to limited efficacy of antibiotic
11 options, hospital hygiene and the resistance of biofilm associated clinical strains (Samadi et
12 al. 2012). Some biofilms also undergo phenotypic change as a result of chemotherapy
13 resulting in increased resistance.

14
15 New insights into biofilm physiology have now enabled researchers to design more
16 effective bacterial inhibition/dispersal strategies. There are two main inhibitory strategies,
17 based on the formulation of new antibiofilm compounds and the construction of biofilm
18 resistant surfaces (Villa and Cappitelli, 2013).

19
20 Some of the most promising candidates for the inhibition of bacterial biofilms have
21 come from biological surface-active agents (biosurfactants) (Kiran et al. 2010; Pradhan et al.
22 2013). Many of these have been reported to have anti-adhesive, antimicrobial and biofilm
23 disruption properties (Rodrigues et al., 2006a,b,c; Rodrigues et al., 2007). Enzymatically
24 synthesized surfactants such as lauryl glucose have also been reported to be effective
25 against fungal and bacterial biofilms (Dusane et al. 2010).

26
27 Biosurfactants are a heterogeneous group of amphiphilic compounds produced
28 mainly by microorganisms that accumulate at the interface between liquid phases and
29 therefore reduce surface and interfacial tension. They have been recognised for some time
30 in a diverse array of potential applications in a wide range of industries including agriculture,
31 food, cosmetic, pharmaceutical and petroleum industries (Banat et al. 2010). The surface

1 and interfacial tension reducing properties of surfactants provide excellent detergency,
2 emulsification, foaming and dispersing traits, making them some of the most versatile
3 products in chemical processes (Desai and Banat 1997). They are highly sought after
4 molecules due to their specificity, low toxicity, high biodegradability, widespread applicability
5 and effectiveness at extremes of pH and temperature (Muthusamy et al. 2008).
6
7
8
9

10
11 Several strands of research have demonstrated that under certain testing conditions
12 biosurfactants can be more effective than many traditional biofilm inhibition and or disruption
13 strategies (Epstein et al. 2011). There have been many reviews of biosurfactants and their
14 potential applications in environmental and biomedical related areas (Neu 1996; Banat et al.
15 2010; Banat et al. 2000). There has been however renewed interest in biosurfactants in
16 relation to healthcare associated infections (Krasowska 2010). In addition, the rapid pace of
17 advances in biofilm inhibition, control/disruption and the emergence of biofilms as potential
18 reservoirs for the dissemination of disease have necessitated a review of the current state of
19 the art on biofilms measurements and potentially effective biosurfactants against microbial
20 biofilms.
21
22
23
24
25
26
27
28
29
30
31
32

33 To our knowledge the area of biofilms and role of biosurfactants within is becoming
34 an increasingly important topic of research yet has not been the subject of a review article. In
35 this review therefore we examine biofilms characteristics, monitoring and quantification and
36 the main classes of current biosurfactants in use, their contribution to the dispersal or
37 inhibition of biofilms, their scope and efficiency, quantification of this dispersal/inhibition and
38 the sources and limitations of their uses.
39
40
41
42
43
44
45
46
47
48

49 **The nature and functions of biosurfactants**

50
51 Biosurfactants are amphiphilic compounds of biological origin containing a hydrophilic region
52 (polar or non-polar) and a hydrophobic region (lipid or fatty acid). The hydrophilic group is
53 the base of the International Union of Pure & Applied Chemistry nomenclature i.e. those
54 biosurfactants containing rhamnose are described as rhamnolipids; while those containing
55 sophorose are sophorolipids and those generally containing a carbohydrate moiety including
56
57
58
59
60
61
62
63
64
65

the previously mentioned two types are described as glycolipids. Other lipopeptide biosurfactants contain a lipophilic hydrocarbon chain described as hydrophobic and a polar or hydrophilic part which is usually composed of a string of amino acids.

Function

Biosurfactants have been identified in many biological processes as the components of cellular metabolism, motion and defence. They are found in great abundance in bacteria, in biofilms, as quorum sensing molecules, lubricants, promoting the uptake of poorly soluble substrates, as immune modulators, virulence factors, secondary metabolites and antimicrobial compounds (Fracchia et al. 2012). In a review by Neu (1996) it has also been proposed that biosurfactants act as important molecules for interfacial processes, conditioning the microbial cell surface, interfaces and surfaces with which the microorganisms interact. These biosurfactants can be found in greater concentrations in the layers of cells associated with movement and hydration although they can have an intracellular location.

Biosurfactants' also have important roles in the dissolution and accessibility of oil molecules especially for oil degrading microorganisms; adhesion to hydrocarbons as a result of the emulsification of water-insoluble substrate compounds; the de-adhesion from interfaces; facilitating the in gliding of bacteria through wetting interfaces. Such surface active molecules can also have a role in enhancing the interaction between microorganisms and all the natural organic hydrophobic compounds interfaces including plant and animal derived polymeric compounds and microbial exopolysaccharides (Neu 1996). The role of bacterial biosurfactants has been extensively studied in *Pseudomonas* where they are known to promote colonisation and migration-dependent structural development (Pamp and Tolker-Nielsen 2007).

Other roles for biosurfactants including biocidal activity have been reported. This is mainly related to the effects of the lipidic moiety against eucaryotic cells. This has also been reported to lead to toxicity, lysis, pyrogenicity, mitogenicity and immunogenicity among other

1 effects (Wicken and Knox 1980). Lysis of red blood cells has been used as a selection
2 criterion for microorganisms producing biosurfactants (Satpute et al. 2009). Finally human
3 derived biosurfactants have recently received increased attention because of their role in
4 immunity and defence (Gakhar et al. 2010).
5
6
7
8
9

10 *Measurements of biosurfactants physical properties*

11 There are many methods employed to test physico-chemical properties of biosurfactants.
12

13 These are very important for base line comparisons. The standard tests are based on the
14 physical properties of biosurfactants such as measurement of reduced surface tension.
15

16 Other tests measure the critical micelle concentration (CMC) which is the concentration of
17 surfactants above which micelle formation occurs. The CMC for example of sodium dodecyl
18 sulphate in water (with no other additives or salts) at 25°C and, atmospheric pressure, is
19 $8 \times 10^{-3} \text{ mol/l}$. The emulsification index (E24 or EI24) is another method used to characterize
20 a biosurfactants' ability to form a stable emulsion with a hydrophobic phase. The hydrophilic
21 phase in this instance is usually water which, can be mixed with Kerosene and the
22 biosurfactant, shaken vigorously and allowed to stand for 24 hours. The percentage
23 emulsion of the water solution in kerosene is reported as the E24 or EI24 (Desai and Banat
24 1997). Other characterisation methods in use are the oscillating jets and the maximum
25 bubble pressures measured in the presence of the surface active compounds.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 *Conditions for monitoring biofilm formation*

46 There is no standard laboratory method for quantifying biofilms though there are preferred
47 methods.. In the past, planktonic bacterial inhibition assays have had to have strictly defined
48 experimental criteria in order to reduce variation in results and increase confidence in
49 antibiotic comparisons. However, these tests do not adequately represent different bacterial
50 growth physiologies such as that in biofilms. The first biofilm tests were very similar to these
51 planktonic experiments and created the impression that biosurfactants were weak
52 counterparts of conventional inhibitory agents. Later, research into biofilm inhibition showed
53
54
55
56
57
58
59
60
61
62
63
64
65

1 that these tests did not give an accurate reflection of the efficacy of biosurfactants. Today's
2 biosurfactant tests are more accurate and try to represent the in-situ environment as much
3 as possible. Many of these tests are based on pre-coating a surface with a known amount of
4 biosurfactant overlaid with microbial biofilm (O'Toole 2011). This can be alternated with
5 overlaying pre-existing biofilms with the test substance.
6
7
8
9

10 Since the biofilm physiology is distinct from the planktonic physiology, biofilm
11 experimental conditions have had to be adjusted accordingly. In terms of temperature the
12 biofilm cultivation is carried out at the optimal temperature for biofilm growth of a particular
13 species which may not be the same as the optimal temperature for planktonic growth, this
14 could mean that biofilm cultivation may be at 20°C (even for clinical specimens) whilst others
15 may be at 10°C in the cases of some environmental biofilms (Quinn et al. 2012).
16
17
18
19
20
21
22
23

24 In terms of nutrition, it is common practice for biofilms to be cultivated in a dilution of the
25 media that is used for planktonic cultivation, this is usually ½ to 1/5th of standard
26 concentrations reflecting the sub-optimal conditions of biofilm growth, however this practice
27 is not universally applicable (Stepanovic et al. 2004).
28
29
30
31
32

33 Since biofilms also grow slower than optimised planktonic conditions, the typical cultivation
34 period for biofilms can vary from 4 hours to 3-4 days or even 7-10 days in the case of slower
35 growing environmental biofilms (Quinn et al. 2012; Stepanovic et al. 2007). Agitation
36 considerations are equally important. In the earliest biofilm growth assays it was thought that
37 environments of high shear stress were necessary. However more recent research has
38 shown that environments of high agitation are not necessary for all biofilm growth and these
39 growth conditions can be considered strain specific. Rather biofilm tests are typically
40 conducted in almost static environments or environments of minimum perturbation (O'Toole
41 2011; Stepanovic et al. 2007).
42
43
44
45
46
47
48
49
50
51
52

53 The standard inoculation density of microorganisms also differs greatly from standard
54 planktonic tests. For planktonic MIC tests organisms are seeded at a density of 1×10^6 /ml of
55 fresh cells taken from the logarithmic stage of growth. In biofilm cultivation seeding densities
56 are typically a 1/100 dilution of a stationary phase culture (McLaughlin and Hoogewerf 2006;
57
58
59
60
61
62
63
64
65

Quinn et al. 2012). Some researchers use biofilm induction agents such as high glucose or alcohol to aid biofilm formation but these may add unknown variables to the assay making the final biofilm data difficult to interpret.

Recently, Lourenco and co-workers (2014) published the results of an initiative to establish “minimum information about a biofilm experiments” (MIABiE) which is a project partly funded by EU grants to find a scientifically adequate procedures to document biofilm-related data. They asserted that this could be achieved through ensuring a set of minimum information that should be reported to guarantee the independent verification and interpretation of experimental results in a way that would allow their integration with biofilm related information generated by other fields.

Surfaces for the quantification of biofilm growth

The physiochemical properties of substrates used for biosurfactant evaluations can affect the nature of biofilm adhesion, the subsequent biofilm architecture in the case of monocultures or the selection of the microbial species which colonise in the case of mixed and environmental biofilms. Biofilms also express different repertoires of proteins or adhesion characteristics depending on the surface characteristics of the substrate they are attached to (Stoodley et al. 2002). Hence the choice of surface for biofilm cultivation is very important and must be taken into account even when comparing the results of inhibitory tests. .

The different surfaces used in biofilm tests range from animate/inanimate, rough/smooth, hydrophobic/ hydrophilic and liquid/air/liquid etc. Laboratory cultivation of biofilms can be conducted on many surfaces including glass, plastic, metal, silicone and tissue models (O'Toole 2011). In more comprehensive assessments of the inhibition potential biosurfactants can be applied to a broad range of surfaces especially in clinical environments. Research into the efficacy of Pseudofactin II (a newly characterised biosurfactant) used many different surfaces such as glass, polystyrene and silicone to cultivate biofilms in combination with different bacterial strains in order to demonstrate its

1 wide efficacy (Janek et al. 2010 & 2012). In other research on biofilms of *Salmonella*,
2 investigators used PVC and silicone (urethral catheters) as biofilm substrates to demonstrate
3 the applicability of biosurfactants in the reduction of biofilm formation/attachment (Mireles et
4 al. 2001).
5
6
7
8
9

10 **Quantification of biofilm inhibition/dispersal**

11 *The Calgary Biofilm Device*

12
13 One of the first devices employed to measure biofilm inhibition/dispersal was the Calgary
14 biofilm device (CBD) (Olson et al. 2002). This technique is widely used in flow tests for
15 microbial biofilms (Rivardo et al. 2009; Girard et al. 2010; Rivardo et al. 2011). The
16 cultivation chamber consists of a 96-well plate together with a lid that contains 96 peg
17 projections (Figure 1). These pegs provide a maximum surface area for the growth of
18 biofilms. The CBD has a typical seeding density of 1×10^4 to 1×10^6 bacteria per well or
19 McFarland standard 1, a cultivation speed of ≥ 10 rpm and an incubation period of 4-24 h
20 depending on species and conditions (Girard et al. 2010).
21
22
23
24
25
26
27
28
29
30
31
32

33 Microbial biofilms are cultivated on test pegs projecting into a growth media, removed
34 after a given time, washed and then inserted into wells containing an inhibitory/test
35 substance. Mature biofilms can be subsequently detached from the pegs by ultrasonic
36 treatment. The detached microbes can be enumerated by standard cultivation techniques or
37 quantified by measuring their optical density at 650 nm. The amount of bacterial inhibition of
38 the biofilms is referred to as the minimal biofilm eradication concentration (MBEC). The
39 MBEC represents the lowest dilution of inhibitory substance. If cultivation conditions require
40 a greater circulation of media the lid of this plate can be modified to accommodate 12 media
41 channels into which the 96 pins are extended.. In this manner 96 pins can be simultaneously
42 exposed to a given culture (Ceri et al 1999)
43
44
45
46
47
48
49
50
51
52
53
54

55 Although the CBD was a welcome departure from planktonic based testing regimes
56 and a step towards a more accurate portrayal of biofilm physiology; the method still relied on
57 the final detection of viable planktonic microorganisms rather than directly measuring the
58
59
60
61
62
63
64
65

whole biofilm biomass. It also assumes that bacteria from viable biofilms can immediately rejuvenate on agar or directly into culture broth. This is an important point in biofilm physiology since studies on the resuscitation of bacterial cells have shown that some microorganisms may still be viable in the biofilm but not immediately cultivatable especially after prolonged chemotherapy (Rollet et al. 2009). This is also important when considering the negative impacts of the selective pressure of chemotherapy on biofilm forming pathogens. In some cases it has been shown that severe chemotherapy can induce a viable but dormant pathogen that can resuscitate in more favourable conditions to contribute to the chronic character of a biofilm infection (Zhang 2014).

Finally, the CBD measures the amount of cells in a biofilm and not the biofilm biomass i.e. the biofilm + extra polymeric substances (EPS). However biofilm substances that are not cells can constitute a significant proportion of biofilms (Decho 2013).

Biofilm growth within flow-through devices

Biofilms can be analysed under flow conditions by a variety of methods including the CBD. However another flow system currently used to test biofilms is the BioFlux 200 system (Fluxion Biosciences Inc., South San Francisco, CA) (Benoit et al. 2010; Ding et al 2014; Chabane et al. 2014). One of the benefits of such a system is that it is amenable to real-time analysis of the biofilm through automated image acquisition within specialized multi-well plates. In order to cultivate biofilms, microfluidic channels are primed with the culture medium at a specific rate. Each channel is seeded with an overnight culture with a cell density of 10^7 CFU. The biofilms are subsequently incubated at specific time and temperature levels in order for the bacterial cells to adhere. Once the biofilms have formed, planktonic cells are removed, and washed. The biofilm growth can then be recorded using a phase contrast or fluorescence microscope (Ding et al. 2014).

In-vitro Biofilm formation in a 8 well chamber

Another variation of biofilm chamber growth is the use of an 8-well chamber slide. This method uses 200µL aliquots of mid-logarithmic cells diluted in fresh medium (1:2500 (v/v)). The medium can be replaced every 12h if the biofilm takes longer than 24h to grow or as needed to maintain bacterial viability (O'Toole 2011).

The resulting biofilms can be visualized by aspirating the medium and washing with saline. The viability of the biofilm cells is typically assessed by the addition of BacLight Live/Dead stain (O'Toole 2011). Additionally, EPS or pili in the biofilms can be visualized under SEM by dehydrating the sample in a graded series of alcohols and adding hexamethyldisilazane (HMDS) (Araujo et al 2003).

Crystal violet quantification of biofilm growth

One of the most commonly used methods to assess the effectiveness of biosurfactants and biofilm inhibitory agents is the crystal violet quantification of biofilm growth (O'Toole 2011). The technique involves the cultivation of a microbial biofilm in a 96-well (high bind PVC) plate, a rinsing step and final staining with 1% crystal violet. Biofilms are quantified by assessing the proportion of crystal violet bound to the biofilm biomass in control and test cultivations. The surfaces of high-bind 96 well plates were originally designed for ELISA tests and hence contain organically compatible high protein binding plastic (other types of PVC have different binding properties). This type of surface allows the binding of large molecules with ionic groups or large hydrophobic regions and permits a wide diversity of bacteria to form biofilms.

The advantages of this method of biofilm quantification is that dispersal/inhibition can be measured directly in-situ rather than extrapolated from viable planktonic microorganisms. The crystal violet stains the total biofilm biomass which includes EPS and extracellular proteins rather than just its component cells. There may be some variability in the results obtained from this test but this can be rectified by a higher number of replicates which is afforded by the 96-well plate.

Quantification of biofilm inhibition by direct analysis

One of the simplest methods of biofilm quantification is by direct measurements of bacterial viability as directly proportional to biofilm dispersal (Rodrigues et al. 2004). This technique does not measure total biofilm biomass or biofilm adhesion, however it is a useful validation step for other methods. This quantification becomes more problematic for mixed bacterial populations and viable but non-cultivable microorganisms.

Bacterial Viability Quantification

There are several viability dyes that are used to quantify biofilm. Most of these are based on DNA binding. These include two of the most widespread fluorescent dyes, propidium iodide which binds to DNA when the cell nuclear membrane is damaged fluorescing red and syto 9 green which binds to DNA when the nuclear membrane is intact (Lehtinen et al. 2004). In the case of biofilms this quantification can be complicated by extracellular DNA but this might only apply in very dense biofilms.

Digital quantification

Fluorescent stains are easily quantified by digital technologies. This makes it easier to assess biofilm growth/dispersal. As mentioned above although this technique may be directly quantitative for bacterial monolayers or biofilms of several layers thick, there are still technical issues however with proportional measurements of complex multi-layered biofilms with all the associated dead spaces and channels.

Other microscopic quantification

Scanning electron microscopy (SEM) has proved to be a useful technique for pictorial representations of biofilms, however the preparation methods involved including successive dehydrations in alcohol and gold sputtering can fundamentally alter the composition and biofilm architecture of biofilms. More promising results have recently been obtained by the use of cryo-SEM (Alhede et al. 2012). As previously stated, the biofilm substrates used in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

microscopic techniques have to be quite robust such as glass; however this may also have a role in determining the formation of the biofilm and cannot always be used in direct comparisons to the same biofilms growth on plastic or silicone.

Biosurfactants as antibiofilm molecules

One of the most common questions posed on the effects of biosurfactants on biofilms is why are there still biofilms when biosurfactants are powerful molecules mostly leading to biofilm inhibition? The current hypothesis is that surface active molecules play a major role in the development and maintenance of biofilms partly through the maintenance of water channels through the biofilm which enhances nutrients movements and gaseous exchange, and which ultimately leads to the dissociation of parts of the biofilm into planktonic mobile forms (Marchant and Banat 2012). However the current focus of research is the ability of biosurfactants to disrupt established biofilms and prevention of the development of new ones. Although there are diverse arrays of biosurfactants, this review focuses on those in current use or known for the ability to disrupt biofilms in-vitro (Table 1).

Lipopeptides biosurfactant as disruptor molecules

Lipopeptides are one of the largest groups of biosurfactants that can effectively disperse microbial biofilms. These generally referred to by their group name although they can be composed of three or more varieties of homologous or congeners molecules. This group includes surfactins, polymixins, fengycins and fusaricidins (Krupovic et al. 2007; Pecci et al. 2010; Raza et al. 2009; Rivardo et al. 2009). Structurally lipopeptides are composed of a hydrophilic peptide attached to hydrophobic lipid or fatty acid. The peptides can either be aliphatic, branched or cyclic. Similarly, the lipids chains can vary in length and conformations ensuring a wide diversity of structures. Many of the current lipopeptides reported to inhibit/disperse biofilms originate from *Bacillus* or *Paenibacillus* (Kim et al. 2009; Price et al. 2007; Quinn et al. 2012).

Polymyxins

Polymyxins, are a class of non-ribosomally synthesized cyclic lipopeptides. They are generally produced as secondary metabolites of *Bacillus* or similar species (Price et al. 2007). Their typical structure is that of a cyclic polypeptide attached to a fatty acid tail. They can also contain exotic bacterial amino acids such as 2, 4, diaminobutyric acid (DAB) (Figure 2A). Polymyxins are known have a limited clinical spectrum of inhibition in the treatment of Gram negative infections. There are several commercially available formulations of polymyxins including Colistin (polymyxin E) (Falagas and Kasiakou 2005), Neosporin and Polymyxin B which can be supplied as polymyxin B sulphate (a mixture of polymyxins) (He et al. 2010). Polymyxin can also be combined with trimethoprim for eye conditions (Polytrim) and with neomycin and bacitracin to make triple antibiotic ointment Neosporin.

Polymyxins are the last drug of choice in some infections and are often prescribed with caution due to fears of their toxicity however this estimation has been reappraised in the light of more rigorous testing (Arnold et al. 2007). Polymyxins are prescribed intestinally or topically as cream or powders in most cases of multi drug resistant *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* (Falagas and Kasiakou 2006; Milletti Sezgin et al. 2012). Polymyxin has been reported to reduce biofilms of *Pseudomonas aeruginosa* at concentrations of 20µg/ml by 99% in a 12 hour time period and almost completely over 24 hours (Jass and Lappin-Scott 1996). However these results are based on the viability of bacteria and not their dispersal; although it was noted that bacterial cells displayed an altered morphology. Polymyxin E (colistin) is recommended as an early aggressive therapy to delay the onset of chronic *P. aeruginosa* infection (which frequently forms biofilms) or intermittent colonization in cystic fibrosis patients, a combination of oral ciprofloxacin with colistin inhalation (Doring et al. 2000).

Polymyxin D1 has been shown to be effective against mixed bacterial biofilms, however our earlier work has shown this compound was found in combination with fusaricidin and surfactin in undefined ratio's (Quinn et al. 2012). This complex of biosurfactants was also reported to inhibit the formation of biofilms of both Gram positive

1 bacteria such as *Staphylococcus aureus*, *Streptococcus bovis*, *Bacillus subtilis* and
2 *Micrococcus luteus* and Gram negative bacteria such as *Pseudomonas aeruginosa*. Most
3
4 interestingly the biosurfactants were able to inhibit the formation of mixed species biofilms
5
6 such as self-assembling marine biofilm (SAMB) in co-incubation assays by 99.3% and
7
8 disrupt previously established mixed SAMB by 72.4% (Quinn et al. 2012).
9

10
11 The mechanism of action of polymyxins on bacterial biofilms remains largely
12
13 undefined. However the mechanism of action on planktonic bacteria is proposed to be
14
15 related to their high affinity for lipopolysaccharide (LPS) (Domingues et al. 2012). This
16
17 induces LPS aggregation increasing the surface charge of LPS leading to internalization and
18
19 binding to the bacterial phosphatidylglycerol-rich membrane leaflets which in turn induces
20
21 leakage of cellular contents (Domingues et al. 2012).
22
23
24
25

26 *Fengycin-like lipopeptides*

27
28 Fengycin-like lipopeptides are derived from *Bacillus subtilis* and *Bacillus licheniformis*.
29
30 These are cyclic lipopeptides containing 8-10 amino acids linked to a beta hydroxy fatty acid
31
32 (Figure 2B). Fengycin-like peptides have also been reported to be involved in the inhibition
33
34 of biofilms (Xu et al. 2013) causing up to 90% dispersion of Gram positive *S. aureus* biofilms
35
36 and up to 97% dispersion of Gram negative *E. coli* biofilm (Rivardo et al. 2009) .
37
38
39
40
41

42 *Putisolvin*

43
44 Putisolvin is a cyclic lipodepsipeptide isolated from *Pseudomonas putida*. This has been
45
46 characterised in two forms, putisolvin I and putisolvin II. This biosurfactant has a four
47
48 member cyclic peptide; the valine residue in putisolvin I being substituted by a leucine or
49
50 isoleucine in putisolvin II. (Figure 2C) (Dubern et al. 2006). Although Putisolvin is involved in
51
52 biofilm formation by *Pseudomonas putida* these surfactants have also been shown to be
53
54 effective dispersal agents in pre- and post-addition to biofilms of other *Pseudomonas* sp.
55
56 strains (Kuiper et al. 2004).
57
58
59
60
61
62
63
64
65

Pseudofactin

Pseudofactin is a cyclic lipodepsipeptide derived from *P. fluorescens*. The structure of Pseudofactin is based on that of a palmitic acid attached to the terminal amino group of an eight amino acid peptide chain. The C-terminal carboxylic group of the last amino acid forms a lactone with the hydroxyl of third amino acid which is a threonine (Figure 2D). Pseudofactin II has been reported to be 36-90% effective against the adhesion of five species of bacterial biofilms on glass, polystyrene and silicone substrates. These strains include *Enterococcus faecalis*, *Escherichia coli*, *Staphylococcus epidermidis*, *Enterococcus hirae* and *Proteus mirabilis*. Similar inhibition of adhesion (92-99%) was reported on yeast biofilms of *Candida albicans* at concentrations of 0.5 mg/ml (Janek et al. 2012).

Pseudofactin has been documented to produce an effective dispersal of 26-70% on pre-existing biofilms grown on untreated surfaces and has been shown to cause a marked inhibition of the initial adhesion of *E. hirae*, *E. coli*, *E. faecalis* and *C. albicans* to silicone urethral catheters. Total growth inhibition of *S. epidermidis* has been observed at the highest concentration tested (0.5 mg/ml), which causes a partial (18-37%) inhibition of other bacteria, a 8-9% inhibition of *C. albicans* yeast growth and a 99% prevention of adhesion (Janek et al. 2012).

Surfactin

Surfactins are one of the most powerful biosurfactants originally isolated from *Bacillus subtilis* and consist of a cyclic peptide heptamer connected to a 13-15 carbon, beta-hydroxy fatty acid chain (Figure 3A). Unfortunately surfactins can also be indiscriminately cytotoxic with haemolytic activities due to its interactions with cellular membranes (D'Auria et al. 2013). They have been reported to inhibit the growth of biofilms of *Salmonella* sp. cultivated on PVC microtitre wells and urethral catheters (Mireles et al. 2001). They have been observed to cause a rippling effect in lipid bilayers perhaps indicating a clue to the mechanism of biosurfactant action or biofilm permeability or integrity (Brasseur et al. 2007)

1 most likely through the formation of some kind of channels within the biofilm increasing
2 penetrability.
3
4
5

6 *Complexes of lipopeptides*

7
8 Although many lipopeptides have been characterised for experimental purposes as pure
9 compounds they are in fact usually associated with groups of similar compounds. This is
10 reflected in their availability as minimally purified preparations. Siram and co-workers (2011)
11 reported on one such complex of lipopeptide biosurfactants produced by a heavy metal
12 tolerant strain of *Bacillus cereus*. This surfactant effectively dispersed biofilms at an active
13 dose of 0.150µg and was noted to be very tolerant of fluxes in pH, temperature and NaCl, in
14 addition to being resistant to high levels of iron, lead and zinc whilst maintaining
15 antimicrobial and biofilm dispersal activity. Another complex of surfactants isolated from
16 *Paenibacillus polymyxa*. PPE was found to consist of polymyxin D1, fusaricidin B and traces
17 of surfactin (Deng et al. 2011; Quinn et al. 2012) (Figure 3 B & C).
18
19
20
21
22
23
24
25
26
27
28
29
30

31 A preparation containing 2mg/ml of such lipopeptides tested in one of our
32 laboratories inhibited (87-98%) the formation of many Gram positive bacterial biofilms such
33 as *Staphylococcus aureus*, *Streptococcus bovis*, *Micrococcus luteus*, *Bacillus subtilis* and
34 also some Gram negative bacteria such as *Pseudomonas aeruginosa* (Quinn et al. 2012).
35 More uniquely in terms of biofilm experiments, this combination of lipopeptides was effective
36 against mixed environmental strains' biofilms formation (99% inhibition) and up to 74% in
37 pre-established biofilms.
38
39
40
41
42
43
44
45
46
47
48

49 *Synergy of lipopeptides with other inhibitors*

50
51 Lipopeptide biosurfactants have been combined with conventional antibiotics in an effort to
52 produce synergistic inhibition effects. Lipopeptides isolated from *Bacillus licheniformis*
53 (strain V9T14) were reported by Rivardo and co-workers (2011) to have a synergistic effect
54 against a mature 24-h uropathogenic *E. coli* (CFT073) biofilms when combined with
55 ciprofloxacin, cefazolin, piperacillin, ceftriaxone, ampicillin, tobramycin and
56
57
58
59
60
61
62
63
64
65

1 trimethoprim/sulfamethoxazole. They concluded that some combinations led to total
2 eradication of biofilm; however the antibiotics on their own had poor inhibitory activity
3
4 (Rivardo et al 2011).
5
6
7

8 *Glycolipid biosurfactants as antibiofilm molecules*

9

10 Glycolipids consist of a carbohydrate attached to aliphatic or hydroxy-aliphatic acid. These
11 are one of the most studied groups of biosurfactants in other fields although they are
12 underrepresented as agents of biofilm dispersal.
13
14
15
16
17
18
19

20 *Rhamnolipids*

21

22 Rhamnolipids consist of di- or mono-rhamnose sugars attached to a fatty acid chain (Figure
23 3 D & E). Originally isolated from *Pseudomonas aeruginosa*, analogues are also produced
24 by isolates of *Burkholderia* (Costa et al. 2011), *Renibacterium salmoninarum*, *Cellulomonas*
25 *cellulans*, *Nocardioides* and *Tetragenococcus koreensis* (Abdel-Mawgoud et al. 2010).
26 Rhamnolipids have been reported as a potential replacement to chemical surfactants for
27 many uses in the oil and petroleum industries and in use for the bioremediation of oil
28 contaminated environments (Marchant and Banat 2012a & b). They are frequently cited as
29 inhibitors of bacterial growth although their capacity to inhibit biofilms however has not been
30 as extensively documented.
31
32
33
34
35
36
37
38
39
40
41

42 Rhamnolipids are involved in biofilm formation in *Pseudomonads* sp. through the
43 promotion of motility, the inhibition of attachment and degradation of the matrix maintaining
44 channels throughout the biofilm for movement of water and oxygen (Boles et al. 2005; Davey
45 et al. 2003). These biosurfactants were previously reported as antibacterial against
46 *Staphylococcus aureus*, *Mycobacterium* sp, *Bacillus* sp, *Serratia marsecens*, *Enterobacter*
47 *aerogenes*, *Klebsiella pneumonia* and against fungi such as *Chaetomium globosum*,
48 *Aureobacidium pullulans*, *Gliocladium virens*, *Botryhs cinerea* and *Rhizoclonia solanii*
49 (Benincasa et al. 2004; Haba et al. 2003).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Rhamnolipids have also been shown to be effective against biofilms of *Bordetella*
2 *bronchiseptica* (Irie et al. 2005). The mechanism of biofilm inhibition is thought to be by the
3 detachment of cells; however some unattached cells may still be viable. They have been
4 reported to disrupt pre-formed biofilms such as *Bacillus pumilus* from the marine
5 environment (on polystyrene microplates) resulting in a dispersal at sub-MIC concentrations
6 and confirming ability to remove pre-formed biofilms (Dusane et al. 2010). This was
7 corroborated by scanning electron microscopy which showed that rhamnolipids removed
8 biofilm-matrix components (Dusane et al. 2010). The effects of rhamnolipids on pre-formed
9 biofilms of *P. aeruginosa* PAO1 generated in our laboratory can be seen here in Figure 4.

10
11 Rhamnolipids were also been tested on devices such as voice prostheses and have
12 been noted to reduce the initial deposition rates of biofilm after 4h (Rodrigues et al. 2006a).
13 A maximum reduction of adhesion ($\approx 66\%$) was observed when the surfaces such as silicone
14 rubber had been preconditioned with rhamnolipids using biofilms of *Streptococcus salivarius*
15 and *Candida tropicalis*. The number of cells adhering after 4h was reduced to $\approx 48\%$ for
16 *Staphylococcus epidermidis*, *Streptococcus salivarius*, *Staphylococcus aureus* and *C.*
17 *tropicalis* in comparison to controls. This group managed to optimise the actions of this
18 biosurfactant on the detachment of microorganisms adhering to silicone rubber by perfusing
19 the flow chamber with a biosurfactant containing solution followed by passage at the liquid-
20 air interface. By this method they were able to achieve a high detachment (96%) for most of
21 the microbial cells.

22
23 Rhamnolipids have also been shown to be effective dispersal agents for fungi
24 disrupting pre-formed biofilms of *Yarrowia lipolytica* on glass surfaces by $\approx 67\%$ which was
25 more effective in comparison to the surfactants cetyl-trimethyl ammonium bromide (CTAB)
26 and sodium dodecyl sulphate (SDS) (Dusane et al. 2012).

27
28 It is important to note that although rhamnolipids can effectively disrupt biofilm
29 formation and integrity which we observed through phase contrast microscopy where thick
30 dense cellular biofilm (Figure 4A) of microcolonies structures on glass coverslips stained
31 with crystal violet was much reduced in after treatment with rhamnolipids biosurfactants

(Figure 4B). These molecules are also known to be extracellular virulence factors and related to the pathogenesis (infection procedure) in *Pseudomonas aeruginosa*. It has been noted that rhamnolipids are also linked to increased lung epithelial permeability, rapid necrotic killing of polymorphonuclear leukocytes and the malfunction of normal tracheal ciliary motion in the respiratory system of infected patients (Read et al. 1992).

Sophorolipids

Sophorose lipids are typical glycolipids biosurfactants consisting of a dimer of sophorose sugar and a long-chain fatty acid that are produced by yeasts belonging to the genus *Candida*.

The synergy between sophorolipids and antibiotics has been studied as potential strategy to disrupt biofilms using The LIVE/DEAD BacLight Bacterial Viability Kits as a method for detection. This method employs two nucleic acid stains — the green-fluorescent SYTO 9® stain and the red-fluorescent propidium iodide stain. These stains differ in their ability to penetrate healthy bacterial cells. When used alone, SYTO 9 stain labels both live and dead bacteria. In contrast, propidium iodide penetrates only bacteria with damaged membranes, reducing SYTO 9 fluorescence when both dyes are present. Thus, live bacteria with intact membranes fluoresce green, while dead bacteria with damaged membranes fluoresce red. Joshi-Navare and Prabhune (2013) reported the the effect of sophorolipds in the disruption of biofilms from *Escherichia coli*. Figure 5 illustrated the examination of cells of *Bacillus subtilis* attached to coverslips after 48h and stained with LIVE/DEAD BacLight showing the presence of individual bacteria, small clusters of cells (microcolonies), and extended areas of the glass surface covered with large numbers of microcolonies of active cells (Figure 5A), as well as, those which their membrane was damage due to the effect of sophorolipids 5% (v/v) concentration after 30min of treatment (Figure 5B).

Other Glycolipids as antibiofilm molecules

Dusane et al. (2012) reported a glycolipid based on glucose and palmitic acid produced by a tropical marine *Serratia marcescens* was effective in inhibiting biofilms of the marine biofouling bacterium *Bacillus pumilus* and the adhesion of *C. albicans* and *P. aeruginosa* PAO1. This effect was also observed with preformed biofilms of these cultures on microtitre plate tests. Other complexes of glycolipids from *Brevibacterium casei* MSA19 have been reported to disrupt and significantly inhibit individual and mixed culture biofilms of human and fish at concentrations of 30 mg/ml (Kiran et al. 2010).

Antibiofilm glycolipids have also been isolated from *Lactobacillus* (Tahmourespour et al. 2011; Zakaria Gomaa 2013). In this case *L. paracasei* A20 produced biosurfactants that inhibit Gram-positive and Gram-negative bacteria, yeasts and filamentous fungi (Gudina et al. 2010). The biosurfactant also showed anti-adhesive activity against pathogenic *Candida albicans*, *Escherichia coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Streptococcus agalactiae*. Glycolipids derived from plants have also been reported to inhibit biofilms. These include a novel hydroxyproline rich glycopeptide from the pericarp of *Datura stramonium* known as datucin which is also reported to eradicate biofilms of antifungal resistant *Candida albicans* (Mandal 2012).

Complex surfactant mixtures

Biosurfactants are seldom found in pure form or isolation and are often associated together with isomers or congeners that share similar physiochemical characteristics which makes the process of purification either exhaustive or uneconomical. However these complexes of biosurfactants may have the advantage of a broader applicability than pure compounds. The same is true of complexes of compounds in other environments; this can be illustrated by the large diversity of antimicrobial peptides and surfactants found on the skin of amphibians (Bevins and Zasloff 1990). Similarly in innate human defence, antimicrobial peptides such as human beta defensins 1, 2 and 3 and related human neutrophil peptides (Ganz et al. 1985) are found in homogenous groups.

Combinations of biosurfactants have also been extracted from *Robinia pseudoacacia* and *Nerium oleander*. These secretions inhibited attachment of biofilms of *Candida albicans* on silicon and denture prosthesis at concentrations of 78µg/ml and 156µg/ml (Cochis et al. 2012). Other biosurfactants obtained from probiotic bacteria *Lactococcus lactis* 53 and *Streptococcus thermophilus* greatly reduced microbial numbers on preconditioned voice prostheses in an artificial throat model and induced a decrease in the airflow resistance that occurs on voice prostheses after biofilm formation (Gakhar et al. 2010).

Biosurfactants from fungi

Biosurfactants that inhibit biofilms have been found in fungi such as *Candida bombicola*. This produces sophorolipids that inhibit biofilms of *V. cholerae* (Mukherji and Prabhune 2014). Other strains of yeast such as *Candida sphaerica* have also been reported to produce biosurfactants such as lunasan (Luna et al. 2011). This inhibits the adhesion of *Pseudomonas aeruginosa*, *Streptococcus agalactiae* and *Streptococcus sanguis* to levels between 80-92%. Similarly rufisan from *Candida lypolytica* inhibits biofilm formation at concentrations greater or equal to 0.75 µg/ml against *S. aureus*, *Streptococcus agalactae*, *S. mutans* NS (Rufino et al. 2011).

Mammalian surface active secretions

From a chemotherapeutical perspective, the most interesting groups of biosurfactants are those produced by humans. Not much is known about these molecules however it has recently been reported that PLUNC ("Palate, lung, nasal epithelium clone") protein has anti-biofilm activity (Gakhar et al. 2010). These molecules are mainly produced as a secretory product of epithelia lining the airways tubes within mammals including humans. They are evolutionarily related to the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family. PLUNC are believed to have novel biologically relevant surface active properties as they significantly reduce surface tension at the air-liquid interface within aqueous solutions they

also inhibited biofilm formation in the airways colonising potential pathogen *Pseudomonas aeruginosa in vitro* at physiologically relevant concentrations (Gakhar et al. 2010).

Conclusions

It has been acknowledged that microbial biofilms lie at the heart of many recalcitrant patient infections in the clinical environment, the dissemination of airborne pathogens and the fouling of industrial surfaces. These problems are increasingly exacerbated by the rise of resistant biofilm populations and the paucity of alternative eradication solutions. Biosurfactants represent an emerging therapy which has inherent anti-bacterial, fungal and viral properties with an ability to effectively disperse or disrupt such biofilms. Their use therefore either on their own or as adjuvants to other antimicrobial chemotherapies may represent a potential way forward in tackling biofilms in the future.

References

- Abdel-Mawgoud AM, Lepine F, Deziel E (2010) Rhamnolipids: diversity of structures, microbial origins and roles. *Appl Microbiol Biotechnol* 86:1323-1336
- Alhede M, Qvortrup K, Liebrechts R, Hoiby N, Givskov M, Bjarnsholt T (2012) Combination of microscopic techniques reveals a comprehensive visual impression of biofilm structure and composition. *FEMS Immunol Med Microbiol* 65: 335-342
- Araujo JC, Téran FC, Oliveira RA, Nour EA, Montenegro MA, Campos JR, Vazoller RF (2003) Comparison of hexamethyldisilazane and critical point drying treatments for SEM analysis of anaerobic biofilms and granular sludge. *J Electron Microsc (Tokyo)* 52:429-33
- Arnold TM, Forrest GN, Messmer KJ (2007) Polymyxin antibiotics for gram-negative infections. *American J Health-system Pharmacy* 64: 819-826
- Banat IM, Franzetti A, Gandolfi I, Bestetti G, Martinotti MG, Fracchia L, Smyth TJ, Marchant R, (2010) Microbial biosurfactants production, applications and future potential. *Appl Microbiol Biotechnol* 87:427-444
- Banat IM, Makkar RS, Cameotra SS (2000) Potential commercial applications of microbial surfactants. *Appl Microbiol Biotechnol* 53:495-508
- Benoit MR, Conant CG, Lonescu-Zanetti C, Schwartz M, Martin A. (2010) New Device for High-Throughput Viability Screening of Flow Biofilms. *App Environ Microbiol* 76: 4136-42
- Benincasa M, Abalos A, Oliveira I, Manresa A (2004) Chemical structure, surface properties and biological activities of the biosurfactant produced by *Pseudomonas aeruginosa* LBI from soapstock. *Antonie Van Leeuwenhoek* 85:1-8
- Bevins CL, Zasloff M (1990) Peptides from frog skin. *Annu Rev Biochem* 59:395-414
- Boles BR, Thoendel M, Singh PK (2005) Rhamnolipids mediate detachment of *Pseudomonas aeruginosa* from biofilms. *Mol Microbiol* 57:1210-1223
- Brasseur R, Braun N, El Kirat K, Deleu M, Mingeot-Leclercq MP, Dufrene YF (2007) The biologically important surfactin lipopeptide induces nanoripples in supported lipid bilayers. *Langmuir* 23:9769-9772

- Bueno J (2014) Anti-Biofilm Drug Susceptibility Testing Methods: Looking for New Strategies against Resistance Mechanism. J Microbial Biochem Technol S3: 004. doi: 10.4172/1948-5948.S3-004
- Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 37:1771-1776
- Chabane NY, Mlouka MB, Alexandre S, Nicol M, Marti S, Pestel-Caron M, Vila J, Jouenne T, Dé (2014) Virstatin inhibits biofilm formation and motility of *Acinetobacter baumannii*. BMC Microbiol 14:62
- Cochis A, Fracchia L, Martinotti MG, Rimondini L (2012) Biosurfactants prevent in vitro *Candida albicans* biofilm formation on resins and silicon materials for prosthetic devices. Oral Surg Oral Med Oral Pathol Oral Radiol 113:755-761
- Croda-García G, Grosso-Becerra V, Gonzalez-Valdez A, Servín-González L, Soberón-Chávez G (2011) Transcriptional regulation of *Pseudomonas aeruginosa* rhlR: role of the CRP orthologue Vfr (virulence factor regulator) and quorum-sensing regulators LasR and RhIR. Microbiol. 157:2545-55
- Costa SG, Deziel E, Lepine F (2011) Characterization of rhamnolipid production by *Burkholderia glumae*. Lett Appl Microbiol 53:620-627
- D'Auria L, Deleu M, Dufour S, Mingeot-Leclercq MP, Tyteca D (2013) Surfactins modulate the lateral organization of fluorescent membrane polar lipids: a new tool to study drug : membrane interaction and assessment of the role of cholesterol and drug acyl chain length. Biochim Biophys Acta 1828:2064-2073
- Davey ME, Caiazza NC, O'Toole GA (2003) Rhamnolipid surfactant production affects biofilm architecture in *Pseudomonas aeruginosa* PAO1. J Bacteriol 185:1027-1036
- Davies D (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114-122
- Decho AW (2013) The EPS matrix as an adaptive bastion for biofilms: introduction to special issue. Int J Mol Sci 14:23297-23300
- Deng Y, Lu Z, Bi H, Lu F, Zhang C, Bie X (2011) Isolation and characterization of peptide antibiotics LI-F04 and polymyxin B6 produced by *Paenibacillus polymyxa* strain JSa-9. Peptides 32:1917-1923

- Desai JD, Banat IM (1997) Microbial production of surfactants and their commercial potential. *Microbiol Mol Biol Rev* 61:47-64
- Ding Y, Wang W, Fan M, Tong Z, Kuang R, Jiang W, Ni L (2014) Antimicrobial and anti-biofilm effect of Bac8c on major bacteria associated with dental caries and *Streptococcus mutans* biofilms. *Peptides* 52:61-7
- Domingues MM, Inacio RG, Raimundo JM, Martins M, Castanho MA, Santos NC (2012) Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane model systems. *Biopolymers* 98:338-344
- Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ (2000) Antibiotic therapy against *Pseudomonas aeruginosa* in cystic fibrosis: a European consensus, *Eur Respiratory J.* 16: 749-767
- Dowd SE, Wolcott RD, Sun Y, McKeenan T, Smith E, Rhoads D (2008) Polymicrobial Nature of Chronic Diabetic Foot Ulcer Biofilm Infections Determined Using Bacterial Tag Encoded FLX Amplicon Pyrosequencing (bTEFAP). *PLoS ONE* 3:e3326
- Dubern JF, Lugtenberg BJ, Bloemberg GV (2006) The ppul-rsaL-ppuR quorum-sensing system regulates biofilm formation of *Pseudomonas putida* PCL1445 by controlling biosynthesis of the cyclic lipopeptides putisolvins I and II. *J Bacteriol* 188:2898-2906
- Dusane DH, Dam S, Nanchaiah YV, Kumar AR, Venugopalan VP, Zinjarde SS (2012) Disruption of *Yarrowia lipolytica* biofilms by rhamnolipid biosurfactant. *Aquat Biosyst* 8:17
- Dusane DH, Nanchaiah YV, Zinjarde SS, Venugopalan VP (2010) Rhamnolipid mediated disruption of marine *Bacillus pumilus* biofilms. *Colloids Surf B Biointerfaces* 81:242-248
- Dusane DH, Pawar VS, Nanchaiah YV, Venugopalan VP, Kumar AR, Zinjarde SS (2011) Anti-biofilm potential of a glycolipid surfactant produced by a tropical marine strain of *Serratia marcescens*. *Biofouling* 27:645-654
- Epstein AK, Pokroy B, Seminara A, Aizenberg J (2011) Bacterial biofilm shows persistent resistance to liquid wetting and gas penetration. *Proc Natl Acad Sci U S A* 108:995-1000
- Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin Infect Dis* 40:1333-1341

- 1 Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the
2 evidence from old and recent studies. Crit Care 10:R27
3
- 4 Fracchia L, Cavallo M, Martinotti MG, Banat IM (2012) Biosurfactants and Bioemulsifiers
5 Biomedical and Related Applications – Present Status and Future Potentials. In:
6 Biomedical Science, Engineering and Technology. pp 325-370
7
8
9
- 10 Gakhar L, Bartlett JA, Penterman J, Mizrahi D, Singh PK, Mallampalli RK, Ramaswamy S,
11 McCray PB (2010) PLUNC is a novel airway surfactant protein with anti-biofilm activity.
12 PLoS ONE 5:e9098
13
14
15
- 16 Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI (1985)
17 Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76:1427-1435
18
19
- 20 Girard LP, Ceri H, Gibb AP, Olson M, Sepandj F (2010) MIC versus MBEC to determine the
21 antibiotic sensitivity of *Staphylococcus aureus* in peritoneal dialysis peritonitis. Perit Dial
22 Int 30:652-656
23
24
25
- 26 Gudina EJ, Rocha V, Teixeira JA, Rodrigues LR (2010) Antimicrobial and antiadhesive
27 properties of a biosurfactant isolated from *Lactobacillus paracasei* ssp. paracasei A20.
28 Lett Appl Microbiol 50:419-424
29
30
31
- 32 Haba E, Pinazo A, Jauregui O, Espuny MJ, Infante MR, Manresa A (2003) Physicochemical
33 characterization and antimicrobial properties of rhamnolipids produced by
34 *Pseudomonas aeruginosa* 47T2 NCBIM 40044. Biotechnol Bioeng 81:316-322
35
36
37
- 38 He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH (2010) Variability of
39 polymyxin B major components in commercial formulations. Int J Antimicrob Agents
40 35:308-310
41
42
43
- 44 Irie Y, O'Toole G A, Yuk MH (2005) *Pseudomonas aeruginosa* rhamnolipids disperse
45 *Bordetella bronchiseptica* biofilms. FEMS Microbiol Lett 250:237-243
46
47
- 48 Janek T, Lukaszewicz M, Krasowska A (2012) Antiadhesive activity of the biosurfactant
49 pseudofactin II secreted by the Arctic bacterium *Pseudomonas fluorescens* BD5. BMC
50 Microbiol 12:24
51
52
53
- 54 Janek T, Lukaszewicz M, Rezanka T, Krasowska A (2010) Isolation and characterization of
55 two new lipopeptide biosurfactants produced by *Pseudomonas fluorescens* BD5 isolated
56 from water from the Arctic Archipelago of Svalbard. Bioresour Technol 101:6118-6123
57
58
59
60
61
62
63
64
65

- 1 Jass J, Lappin-Scott HM (1996) The efficacy of antibiotics enhanced by electrical currents
2 against *Pseudomonas aeruginosa* biofilms. J Antimicrob Chemother 38:987-1000
3
- 4 Joshi-Navare K, Prabhune A (2013) A biosurfactant sophorolipid acts in synergy with
5 antibiotics to enhance their efficiency BioMed Res Int; 1-8
6
7
- 8 Kim KM, Lee JY, Kim CK, Kang JS (2009) Isolation and characterization of surfactin
9 produced by *Bacillus polyfermenticus* KJS-2 . Arch Pharm Res 32:711-715
10
11
- 12 Kiran GS, Sabarathnam B, Selvin J (2010) Biofilm disruption potential of a glycolipid
13 biosurfactant from marine *Brevibacterium casei*. FEMS Immunol Med Microbiol 59:432-
14 438
15
16
- 17 Kotulova D, Slobodnikova L (2010) Susceptibility of *Staphylococcus aureus* Biofilms to
18 Vancomycin, Gentamicin and Rifampin. Epidemiologie Mikrobiologie Imunologie 59:
19 80-87
20
21
22
23
- 24 Krasowska A (2010) Biomedical activity of biosurfactants. Postepy Hig Med Dosw) 64:310-
25 313
26
27
- 28 Krupovic M, Daugelavicius R, Bamford DH (2007) Polymyxin B induces lysis of marine
29 *Pseudoalteromonads* Antimicrob Agents. Chemother 51:3908-3914
30
31
32
- 33 Kuiper I, Lagendijk, EL, Pickford, R, Derrick, JP, Lamers, GEM, Thomas-Oates, JE,
34 Lugtenberg, BJJ, Bloemberg, GV (2004) Characterization of two *Pseudomonas putida*
35 lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and break
36 down existing biofilms. Mol Microbiol 51:97-113
37
38
39
- 40 Lehtinen J, Nuutila J, Lilius, EM (2004) Green fluorescent protein-propidium iodide (GFP-PI)
41 based assay for flow cytometric measurement of bacterial viability. Cytometry 60A: 165-
42 172
43
44
45
- 46 Leis AP, Schlicher S, Franke H, Strathmann M (2005) Optically transparent porous medium
47 for nondestructive studies of microbial biofilm architecture and transport dynamics. Appl
48 Environ Microbiol 71:4801-4808
49
50
51
- 52 Liu L, Tan X, Jia A (2012) Relationship between bacterial quorum sensing and biofilm
53 formation--a review. Acta microbiologica Sinica 52: 271-278.
54
55
56
- 57 Lourenco A, Machado H, Brito L (2011) Biofilms of *Listeria monocytogenes* produced at 12
58 degrees C either in pure culture or in co-culture with *Pseudomonas aeruginosa* showed
59 reduced susceptibility to sanitizers. J Food Sci 76: M143-148
60
61
62
63
64
65

- 1 Lourenco A, Coenye T, Goeres DM, Donelli G, Azevedo AS, Ceri H, Coelho FL, Flemming
2 HC, Juhna T, Lopes SP, Oliveira R, Oliver A, Shirtliff ME, Sousa AM, Stoodley P,
3 Pereira MO, Azevedo NF (2014) Minimum information about a biofilm experiment
4 (MIABiE): standards for reporting experiments and data on sessile microbial
5 communities living at interfaces. *Pathogens and Disease* 70: 250-256
6
7
8
9 Luna JM, Rufino RD, Sarubbo LA, Rodrigues LR, Teixeira JA, de Campos-Takaki GM
10 (2011) Evaluation antimicrobial and antiadhesive properties of the biosurfactant
11 Lunasan produced by *Candida sphaerica* UCP 0995. *Curr Microbiol* 62:1527-1534
12
13
14
15 Mandal SM (2012) A novel hydroxyproline rich glycopeptide from pericarp of *Datura*
16 *stramonium*: proficiently eradicate the biofilm of antifungals resistant *Candida albicans*.
17 *Biopolymers* 98:332-337
18
19
20
21 Marchant R, Banat IM (2012a) Biosurfactants: a sustainable replacement for chemical
22 surfactants? *Biotechnol Lett* 34:1597-1605
23
24
25 Marchant R, Banat IM (2012b) Microbial biosurfactants: challenges and opportunities for
26 future exploitation. *Trends Biotechnol* 30:558-565
27
28
29 McLaughlin RA, Hoogewerf AJ (2006) Interleukin-1beta-induced growth enhancement of
30 *Staphylococcus aureus* occurs in biofilm but not planktonic cultures. *Microb Pathog*
31 41:67-79
32
33
34
35 Milletti Sezgin F, Coban AY, Gunaydin M (2012) Investigation of biofilm formation in
36 *Acinetobacter baumannii* isolates and their colistin susceptibilities in biofilm. *Int J*
37 *Antimicrob Agents* 41:199
38
39
40
41 Mireles JR, 2nd, Toguchi A, Harshey RM (2001) *Salmonella enterica* serovar *typhimurium*
42 swarming mutants with altered biofilm-forming abilities: surfactin inhibits biofilm
43 formation. *J Bacteriol* 183:5848-5854
44
45
46
47 Mukherji R, Prabhune A (2014) Novel glycolipids synthesized using plant essential oils and
48 their application in quorum sensing inhibition and as antibiofilm agents. *Scientific World*
49 *Journal* 2014: 890709
50
51
52
53 Muthusamy K, Gopalakrishnan S, Ravi TK, Sivachidambaram P (2008) Biosurfactants:
54 Properties, commercial production and application. *Current Sci.* 94: 736-747
55
56
57 Neu TR (1996) Significance of bacterial surface-active compounds in interaction of bacteria
58 with interfaces. *Microbiological Reviews* 60: 151-166
59
60
61
62
63
64
65

- O'Toole GA (2011) Microtiter dish biofilm formation assay. J Vis Exp Jan 30;(47). pii: 2437. doi: 10.3791/2437.
- Olson ME, Ceri H, Morck DW, Buret AG, Read RR (2002) Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 66:86-92
- Pamp SJ, Tolker-Nielsen T (2007) Multiple roles of biosurfactants in structural biofilm development by *Pseudomonas aeruginosa*. J Bacteriol 189:2531-2539
- Pecci Y, Rivardo F, Martinotti MG, Allegrone G (2010) LC/ESI-MS/MS characterisation of lipopeptide biosurfactants produced by the *Bacillus licheniformis* V9T14 strain. J Mass Spectrom 45:772-778
- Pereira MO, Machado I, Simões M, Vieira MJ (2007) Preventing biofilm formation using surfactants. BiofilmClub©. 167-74. <http://hdl.handle.net/1822/7534> accessed May 2014.
- Pradhan AK, Pradhan N, Mall G, Panda HT, Sukla LB, Panda PK, Mishra BK (2013) Application of lipopeptide biosurfactant isolated from a halophile: *Bacillus tequilensis* CH for inhibition of biofilm. Appl Biochem Biotechnol 171:1362-1375
- Price NP, Rooney AP, Swezey JL, Perry E, Cohan FM (2007) Mass spectrometric analysis of lipopeptides from *Bacillus* strains isolated from diverse geographical locations. FEMS Microbiol Lett 271:83-89
- Quinn GA, Maloy AP, McClean S, Carney B, Slater JW (2012) Lipopeptide biosurfactants from *Paenibacillus polymyxa* inhibit single and mixed species biofilms. Biofouling 28:1151-1166
- Raza W, Yang X, Wu H, Wang Y, Xu Y, Shen Q (2009) Isolation and characterisation of fusaricidin-type compound-producing strain of *Paenibacillus polymyxa* SQR-21 active against *Fusarium oxysporum* f.sp.nevium. Eur J Plant Pathol 125:471-483
- Read RC, Roberts P, Munro N, Rutman A, Hastie A, Shryock T, Hall R, McDonald-Gibson W, Lund V, Taylor G (1992) Effect of *Pseudomonas aeruginosa* rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 72: 2271–2277
- Rivardo F, Martinotti MG, Turner RJ, Ceri H (2011) Synergistic effect of lipopeptide biosurfactant with antibiotics against *Escherichia coli* CFT073 biofilm. Int J Antimicrob Agents 37:324-331

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Rivardo F, Turner RJ, Allegrone G, Ceri H, Martinotti MG (2009) Anti-adhesion activity of two biosurfactants produced by *Bacillus* spp. prevents biofilm formation of human bacterial pathogens. *Appl Microbiol Biotechnol* 83:541-553
- Rodrigues L, Banat IM, Teixeira J, Oliveira R (2006a) Biosurfactants: potential applications in medicine. *J Antimicrob Chemother* 57:609-618
- Rodrigues L, Banat IM, van der Mei HC, Teixeira JA, Oliveira R (2006b) Interference in adhesion of bacteria and yeasts isolated from explanted voice prostheses to silicone rubber by rhamnolipid biosurfactants. *J Appl Microbiol* 100:470-480
- Rodrigues L, van der Mei HC, Banat IM, Teixeira J, Oliveira R (2006c) Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from *Streptococcus thermophilus* A. *FEMS Immunology and Medical Microbiology* 46, 107-112
- Rodrigues L, van der Mei HC, Teixeira J, Oliveira R (2004) Influence of biosurfactants from probiotic bacteria on formation of biofilms on voice prostheses. *Appl Environ Microbiol* 70:4408-4410
- Rodrigues L, Banat IM, Teixeira J, Oliveira R (2007) Strategies for the prevention of microbial biofilm formation on silicone rubber voice prostheses. *J Biomed Materials Res Part B- Applied Biomaterials* 81B: 358-370
- Rollet C, Gal L, Guzzo J (2009) Biofilm-detached cells, a transition from a sessile to a planktonic phenotype: a comparative study of adhesion and physiological characteristics in *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* 290:135-142
- Rufino RD, Luna JM, Sarubbo LA, Rodrigues LR, Teixeira JA, Campos-Takaki GM (2011) Antimicrobial and anti-adhesive potential of a biosurfactant Rufisan produced by *Candida lipolytica* UCP 0988. *Colloids Surf B Biointerfaces* 84:1-5
- Satpute SK, Banpurkar AG, Dhakephalkar PK, Banat IM, Chopade BA (2009) Methods for investigating biosurfactants and bioemulsifiers: A review. *Critical Reviews in Biotechnol* 30: 127-144
- Samadi N, Abadian N, Ahmadkhaniha R, Amini F, Dalili D, Rastkari N, Safaripour E, Mohseni FA (2012) Structural characterization and surface activities of biogenic rhamnolipid surfactants from *Pseudomonas aeruginosa* isolate MN1 and synergistic effects against methicillin-resistant *Staphylococcus aureus*. *Folia Microbiologica* 57: 501-508

- 1 Sepandj F, Ceri H, Gibb A, Read R, Olson M (2004) Minimum inhibitory concentration (MIC)
2 versus minimum biofilm eliminating concentration (MBEC) in evaluation of antibiotic
3 sensitivity of gram-negative bacilli causing peritonitis. *Perit Dial Int* 24:65-67
4
- 5 Sriram MI, Kalishwaralal K, Deepak V, Gracerosept R, Srisakthi K, Gurunathan S (2011)
6 Biofilm inhibition and antimicrobial action of lipopeptide biosurfactant produced by heavy
7 metal tolerant strain *Bacillus cereus* NK1. *Colloids Surf B Biointerfaces* 85:174-181
8
- 9 Stepanovic S, Cirkovic I, Ranin L, Svabic-Vlahovic M (2004) Biofilm formation by *Salmonella*
10 spp. and *Listeria monocytogenes* on plastic surface. *Lett Appl Microbiol* 38:428-432
11
- 12 Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F (2007)
13 Quantification of biofilm in microtiter plates: overview of testing conditions and practical
14 recommendations for assessment of biofilm production by *staphylococci* . *APMIS*
15 115:891-899
16
- 17 Stewart CR, Muthye V, Cianciotto NP (2012) *Legionella pneumophila* Persists within Biofilms
18 Formed by *Klebsiella pneumoniae*, *Flavobacterium* sp., and *Pseudomonas fluorescens*
19 under Dynamic Flow Conditions *PLoS ONE* 7:e50560
20
- 21 Stoodley P, Sauer K, Davies DG, Costerton JW (2002) Biofilms as complex differentiated
22 communities. *Annu Rev Microbiol* 56:187-209
23
- 24 Tahmourespour A, Salehi R, Kasra Kermanshahi R (2011) *Lactobacillus acidophilus*-Derived
25 Biosurfactant Effect on GTFB and GTFC Expression Level in *Streptococcus mutans*
26 Biofilm Cells. *Braz J Microbiol* 42:330-339
27
- 28 Velraeds MMC, van de Belt-Gritter B, Busscher HJ, Reid G, van der Mei HC (2000)
29 Inhibition of uropathogenic biofilm growth on silicone rubber in human urine by
30 *lactobacilli* - a teleologic approach. *World J Urology* 18: 422-426
31
- 32 Villa, F, Cappitelli, F (2013) Plant-derived bioactive compounds at sub-lethal concentrations:
33 towards smart biocide-free antibiofilm strategies. *Phytochem Rev* 12: 245-254
34
- 35 Wicken AJ, Knox KW (1980) Bacterial cell surface amphiphiles. *Biochim. Biophys. Acta* 604:
36 1–26. Wu ZY, Ye CS, ; Guo F, Zhang SH, Yu X (2013) Evidence for Broad-Spectrum
37 Biofilm Inhibition by the Bacterium *Bacillus* sp Strain SW9. *Appl Environ Microbiol* 79:
38 1735-1738
39
- 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Xu Z, Shao J, Li B, Yan X, Shen Q, Zhang R (2013) Contribution of Bacillomycin D in
2 *Bacillus amyloliquefaciens* SQR9 to Antifungal Activity and Biofilm Formation. Appl
3 Environ Microbiol 79: 808-815
4

5 Zakaria Gomaa E (2013) Antimicrobial and anti-adhesive properties of biosurfactant
6 produced by *Lactobacilli* isolates, biofilm formation and aggregation ability. J Gen Appl
7 Microbiol. 2013;59 :425-36
8
9

10 Zhang Y (2014) Persisters, persistent infections and the Yin-Yang model. Emerg Microbes
11 Infect 3: e3. Published online: doi:10.1038/emi.2014.3
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 Selected biosurfactants reported in literature with antibiofilm/microbial activities.

Biosurfactant class	Name	Source	Reference	Effectiveness
Lipopeptide	Putisolvin I & II	<i>Pseudomonas putida</i>	Kuiper et al. 2004	Biofilm inhibition of <i>Pseudomonas</i> spp.
Lipopeptide	Pseudofactin II		Janek et al. 2010	Effective against <i>E. coli</i> , <i>Enterococcus faecalis</i> , <i>Proteus mirabilis</i> and <i>Candida</i> sp.
Lipopeptide	NS	<i>Bacillus subtilis</i>	Mireles et al. 2001	Biofilm inhibition of <i>S. entrica</i> on urethral catheter
Lipopeptide	Fengycin	<i>B. subtilis</i> & <i>B. licheniformis</i>	Rivardo et al. 2009	Inhibition of pathogenic <i>E. coli</i> & <i>S. entrica</i>
Lipopeptide	NS	Heavy metal tolerant strain of <i>Bacillus</i>	Sriram et al. 2011	Inhibits Gram positive and negative bacteria and fungi
Lipopeptide	NS	<i>Bacillus</i> sp. strain SW9	Wu et al. 2013	Inhibits biofilm formation in a wide range of bacteria
Lipopeptide	NS	<i>Bacillus tequilensis</i>	Pradhan et al. 2013	Biofilm inhibition of <i>E. coli</i> & <i>Streptococcus mutans</i>
Lipopeptide	L. fermentum B54	<i>Lactobacillus</i>	Velraeds et al. 2000	Inhibits uropathogens
Glycolipids	NS	<i>Brevibacterium casei</i> .	Kiran et al. 2010	Inhibits mixed pathogenic biofilm bacteria
Mixture of biosurfactants	Lunasan	<i>Candida sphaerica</i>	Luna et al. 2011	Inhibition of <i>P. aeruginosa</i> and <i>S. agalactae</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

NS	NS	<i>Lactobacillus paracasei</i> A20	Gudina et al. 2010	Biofilm inhibition for a range of bacteria, yeasts & filamentous fungi.
Glycolipid	Rhamnolipid	<i>P. aeruginosa</i>	Rodrigues et al. 2006b	Inhibits biofilms in <i>S. aureus</i> <i>Candida tropicalis</i>
Glycolipid	Rhamnolipid	<i>P. aeruginosa</i>	Dusane et al. 2010	Inhibits <i>B. pumilus</i>
Mixed biosurfactants		<i>Lactococcus lactis</i> / <i>Strep thermophilus</i>	Rodrigues et al. 2004	Effective against <i>Staphylococcus</i> , <i>Streptococcus</i> , <i>Rothia</i> and <i>Candida sp.</i>
NS	NS	<i>Robinia pseudocacia</i> / <i>Nerium oleander</i>	Cochis et al. 2012	Effective against <i>C. albicans</i>
Glycolipids	Rhamnolipid	<i>P. aeruginosa</i>	Dusane et al. 2012	Effective against <i>Yarrowia sp.</i>
NS	Rufisan	<i>Candida lypolytica</i>	Rufino et al. 2011	Effective against <i>Streptococcus sp</i>
Glycolipid	Glucose + palmitic acid	<i>Serratia Marsecens</i>	Dusane et al. 2011	Effective against <i>C. albicans</i> , <i>P. aeruginosa</i> and <i>B. pumilus</i>

NS= Not specified

Figures legends

Figure 1. Calgary Biofilm Device (CBD) measures the minimum biofilm eradication concentration (MBEC). (1) Biofilms cultivated on pegs in 1/10th Muller Hinton broth (2) Pegs rinsed with PBS (3) Pegs exposed to test substances in new wells (4) Pegs rinsed in PBS (5) Biofilm removed by sonicating pegs into sterile media (6) Remaining viable bacteria in wells is proportional to the biofilm biomass.

Figure 2. Biosurfactants: (A) Polymyxin B2, (B) Fengycin-like peptide, (C) Putisolvin II and (D) Pseudofactin II:

Figure 3. Biosurfactants : (A) Surfactin, (B) - Polymyxin D1, (C) Fusaricidin B1, (D) Rhamnolipids: mono rhamnolipid, (l-rhamnosyl- β -hydroxydecanoyl- β -hydroxydecanoate)(RL-1) and (E) di-rhamnolipid, (l-rhamnosyl l-rhamnosyl- β -hydroxydecanoyl- β -hydroxydecanoate (RL-2), DAB = diaminobutyric acid.

Figure 4. Representative images depicting the effect of rhamnolipids on pre-formed biofilms of *P. aeruginosa* PAO1 on cover slips. Cells were stained with crystal violet 1%, and observed using a phase contrast microscope at 40x. (A) *P. aeruginosa* PAO1 Biofilms after 48h. (B) After 30min treatment with rhamnolipids (5%) v/v on 48h biofilms.

Figure 5. Biofilm formation by *Bacillus subtilis* BBK006 on coverslips. Cells were stained with Syto9®, and observed using a fluorescence microscope at 40x. The bar represent 100 μ m . (A) *Bacillus subtilis* BBK006 biofilms after 48h as a control. (B) After 30min treatment in the presence of Sophorolipids 5% v/v on 48h preformed biofilms.

Figure 1



Biofilms cultivated in wells
with pegs



Biofilms mature



Non-adherent bacteria
rinsed off



Biofilms incubated with
test substance



Rinse off inhibitor



Sonicate pegs into media
growth = biofilm survival

Figure 2






Figure 3


A




B



C



D



E




Figure 4




Figure 5

